Efficacy of topical corticosteroids in the treatment of primary phimosis in children and adolescents
DOI:
https://doi.org/10.5712/rbmfc12(39)1454Keywords:
Adrenal Cortex Hormones. Phimosis. Therapeutics. Child. Adolescent.Abstract
Introduction: Primary phimosis is a frequent problem in child health clinic with a prevalence of 11% at 3 years of age. Objective: The aim of this review is to evaluate the efficacy of topical corticosteroids (CCT) in reduction of foreskin retractile limitation in children and adolescents. Methods: The research was performed using the National Guideline Clearing House, Canadian Medical Association Practice Guidelines InfoBase, Cochrane Library, DARE, Bandolier, Evidence Based Medicine Online, Trip Database Online and PubMed databases using the terms “phimosis and steroids”. Clinical guidelines, meta-analyses, systematic reviews and randomized controlled trials (RCTs) were searched in Portuguese, English and Spanish. The Levels of Evidence of Oxford Centre for Evidence Based Medicine were used. Results: A total of 148 articles were found, of which only six fulfilled the inclusion criteria: one guideline and five RCTs. Since 2013 the European Society of Pediatric Urology recommends the use of CCT in primary phimosis. The RCTs included a total of 624 children and adolescents aged between zero and 15 years and different CCTs and therapeutic approaches were tested. A significant improvement in prepuce retraction was observed with the use of CCT compared to placebo achieving a therapeutic efficacy of 66% and 90%. Conclusion: The studies used in this work support the use of CCTs in the treatment of primary phimosis in children and adolescents. However, we consider to be of added value the implementation of larger and methodologically homogeneous studies in order to clarify what is the best CCT therapeutic method.
Downloads
Metrics
References
Gairdner D. The fate of the foreskin, a study of circumcision. Br Med J. 1949;2(4642):1433-7. DOI: http://dx.doi.org/10.1136/bmj.2.4642.1433 DOI: https://doi.org/10.1136/bmj.2.4642.1433
Shim YH, Lee JW, Lee SJ. The risk factors of recurrent urinary tract infection in infants with normal urinary systems. Pediatr Nephrol. 2009;24(2):309-12. DOI: http://dx.doi.org/10.1007/s00467-008-1001-0 DOI: https://doi.org/10.1007/s00467-008-1001-0
Phimosis and Paraphimosis [Internet]. 2016 [cited 2016 Dec 31]. Available from: http://emedicine.medscape.com/article/777539-overview#a4
Programa Nacional de Saúde Infantil e Juvenil. In: Norma da Direção-Geral da Saúde. Lisboa: DGS; 2013.
Pileggi Fde O, Vicente YA. Phimotic ring topical corticoid cream (0.1% mometasone furoate) treatment in children. J Pediatr Surg. 2007;42(10):1749-52. DOI: http://dx.doi.org/10.1016/j.jpedsurg.2007.05.035 DOI: https://doi.org/10.1016/j.jpedsurg.2007.05.035
Nobre YD, Freitas RG, Felizardo MJ, Ortiz V, Macedo Jr A. To circ or not to circ: clinical and pharmacoeconomic outcomes of a prospective trial of topical steroid versus primary circumcision. Int Braz J Urol. 2010;36(1):75-85. DOI: http://dx.doi.org/10.1590/S1677-55382010000100012 DOI: https://doi.org/10.1590/S1677-55382010000100012
Ng WT, Fan N, Wong CK, Leung SL, Yuen KS, Sze YS, et al. Treatment of childhood phimosis with a moderately potent topical steroid. ANZ J Surg. 2001;71(9):541-3. DOI: http://dx.doi.org/10.1046/j.1440-1622.2001.02190.x DOI: https://doi.org/10.1046/j.1440-1622.2001.02190.x
Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol Suppl (Stockh). 1989;151:7-10.
The Oxford 2011 Levels of Evidenc [Internet]. 2011 [cited 2017 Aug 11]. Available from: http://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-of-Evidence-2.1.pdf
Esposito C, Centonze A, Alicchio F, Savanelli A, Settimi A. Topical steroid application versus circumcision in pediatric patients with phimosis: a prospective randomized placebo controlled clinical trial. World J Urol. 2008;26(2):187-90. DOI: http://dx.doi.org/10.1007/s00345-007-0231-2 DOI: https://doi.org/10.1007/s00345-007-0231-2
Lund L, Wai KH, Mui LM, Yeung CK. An 18-month follow-up study after randomized treatment of phimosis in boys with topical steroid versus placebo. Scand J Urol Nephrol. 2005;39(1):78-81. DOI: http://dx.doi.org/10.1080/00365590410002519 DOI: https://doi.org/10.1080/00365590410002519
Letendre J, Barrieras D, Franc-Guimond J, Abdo A, Houle AM. Topical triamcinolone for persistent phimosis. J Urol. 2009;182(4 Suppl):1759-63. DOI: http://dx.doi.org/10.1016/j.juro.2009.03.016 DOI: https://doi.org/10.1016/j.juro.2009.03.016
Lee JW, Cho SJ, Park EA, Lee SJ. Topical hydrocortisone and physiotherapy for nonretractile physiologic phimosis in infants. Pediatr Nephrol. 2006;21(8):1127-30. DOI: http://dx.doi.org/10.1007/s00467-006-0104-8 DOI: https://doi.org/10.1007/s00467-006-0104-8
Tekgül S, Riedmiller H, Dogan HS, Erdem E, Hoebeke P, Kocvara R, et al. Guidelines on Pediatric Urology. European Society for Pediatric Urology Guidelines; 2013 [cited 2017 Aug 11]. Available from: https://uroweb.org/wp-content/uploads/22-Paediatric-Urology_LR.pdf
Downloads
Published
How to Cite
Issue
Section
License
By submitting a manuscript to the RBMFC, authors retain ownership of the copyright in the article, and authorize RBMFC to publish that manuscript under the Creative Commons Attribution 4.0 license and identify itself as the vehicle of its original publication.
